Copyright
©The Author(s) 2015.
World J Clin Oncol. Aug 10, 2015; 6(4): 64-72
Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.64
Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.64
Adverse events | Pre-chemotherapyincidence (95%CI) | Post-chemotherapyincidence (95%CI) |
Cardiac disorders all-grade | 3.0% (1.9%-4.8%) | 4.0% (2.8%-5.6%) |
Fluid retention and edema all-grade | 4.0% (2.6%-6.0%) | 9.0% (7.2%-11.2%)b |
Hypertension all-grade | 9.0% (6.9%-11.7%) | 3.0% (2.0%-4.4%)b |
Hypokalemia all-grade | 9.0% (7.2%-11.2%) | 4.0% (2.6%-6.0%)b |
Hypokalemia high-grade | 0.1% (1.0%-1.5%) | 3.7% (2.6%-5.2%)b |
- Citation: Shameem R, Hamid MS, Xu KY, Wu S. Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer. World J Clin Oncol 2015; 6(4): 64-72
- URL: https://www.wjgnet.com/2218-4333/full/v6/i4/64.htm
- DOI: https://dx.doi.org/10.5306/wjco.v6.i4.64